MODERATOR: Paul Hingst, Supply Chain Consultant, Crinetics
China’s pharmaceutical innovation stands at a pivotal inflection point. After a decade of explosive growth, the industry is navigating a period of “capital winter,” intense policy-driven competition, and a strategic shift from the pursuit of quantity to the mandate of quality. However, this pressure is also a catalyst, forcing a clear-eyed re-evaluation of the path forward. Today, China is not just a vast clinical trial hub or a manufacturing powerhouse; it is defining its ambition to become a “world new drug creation center” by 2035.
中国医药创新正站在一个关键的历史转折点。经历十年高速发展之后，行业步入“资本寒冬”，政策驱动的同质化竞争日趋激烈，发展逻辑正从追求数量向锚定质量深刻转型。然而，压力亦是催化剂，正倒逼全行业以更清醒的姿态重新审视前路。今天，中国不再仅仅是全球临床试验的聚集地或制药生产基地，它正在以2035年建成“世界级新药创制中心”为愿景，重新定义自己的全球坐标。
Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Hosted by industry experts and each focused on a single issue, roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.
Roundtable session lasts for 30 minutes and rotate
ROUNDTABLE 1: How do we measure and incentivize long-term patient engagement and retention beyond the duration of a single trial?
ROUNDTABLE 2: How do we transition from a cost-center logistics function to a value-creating strategic asset?
ROUNDTABLE 3: What will it take for a Chinese company to be perceived as a peer and leader by the global biopharma ecosystem?
互动式圆桌讨论为您提供一个与同行深度交流的独特机会，共同分享最佳实践，探讨行业面临的共性挑战并寻求解决方案。每场圆桌由行业专家主持，聚焦单一议题，以高互动性的形式助您拓展人脉网络，汲取同侪的经验与洞见。
每场圆桌讨论时长为30分钟，设有轮换环节。
圆桌讨论1
单次试验结束后，我们如何衡量并激励患者的长期参与和保留？
圆桌讨论2
物流职能如何从“成本中心”转型为“价值创造型战略资产”？
圆桌讨论3
中国公司如何被全球生物医药生态视为平起平坐的同行乃至领导者？